A retrospective review was conducted to assess the effect of molindone on weight. Monthly weights and neuroleptic dosages during the first three months of psychiatric hospitalization were compared between matched groups of patients receiving molindone, a combination of molindone and other neuroleptics, or other neuroleptic drugs. We found no significant differences in weight gain among the three groups. Our results challenge the common opinion that molindone can be associated with a lack of weight gain compared to other antipsychotics.
ClaghornJ. Review of clinical and laboratory experience with molindone hydrochloride. J Clin Psychiatry1985; 46: 30–3.
2.
AmdisenA. Drug-produced obesity: experience with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull1964; 11: 182–9.
3.
RockwellWJEllinwoodEHTraderDW. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J1983; 76: 1407–12.
4.
GopalaswarnyAKMorganR. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand1985; 72: 254–28.
5.
KrumholtzWVSheppardCMerlisS. Menstruation changes as unusual side effects in a molindone trial. Curr Ther Res1970; 12: 94–6.
6.
ClarkMLHuberWKSakataK. Molindone in chronic schizophrenia. Clin Pharmacol Ther1970; 11: 680–8.
7.
AbuzzahabFS. Long term use of molindone in schizophrenics. J Clin Pharmacol1973; 11: 422–6.
8.
SugarmanAAHermanJ. Molindone: an indole derivative with anti-psychotic activity. Clin Pharmacol Ther1967; 8: 261–5.
9.
GallantDMBishopMP. Molindone: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res1968; 10: 441–7.
10.
GardosGColeJ. Weight reduction in schizophrenics by molindone. Am J Psychiatry1977; 143: 302–4.
11.
HollisterLE. Antipsychotic medications and the treatment of schizophrenia. In: BarchasJBergerPCiaranelloRElliotG, eds. Psychopharmacology. New York: Oxford Press, 1977: 137.
